] B (n = 6) (−59%, P = 0.0004). A significant negative correlation was observed between IMPA2 mRNA levels and [Ca 2+ ] B in BLCLs from male (P = 0.046), but not female BD-I patients. Sex-dependent differences were also evident in postmortem temporal cortex IMPA2 mRNA levels which, in contrast to BLCLs, were significantly higher in male BD-I subjects compared with male controls (P = 0.025, n = 4/group). Collectively, these observations suggest a potential sex-dependent link between abnormalities in IMPA2 expression and calcium homeostasis in the pathophysiology of BD. Molecular Psychiatry (2001) 6, 678-683.
Introduction
Although the etiopathogenesis of bipolar affective disorder (BD) is still uncertain, family, adoption and twin studies strongly suggest that genetic factors play a key role in the transmission of this disorder. 1 Segregation analyses have failed to support a single gene locus model of the illness, however. This, together with the difficulties of genome-scanning studies to consistently identify potential susceptibility loci, even with two or three-locus modeling, suggests that significant genetic heterogeneity and/or epistatic interaction of multiple genes occurs in BD, leading to the view that BD is a complex trait disorder. 1 This notion, together with the limitations in clinical definition of affecteds, has renewed interest in identifying more distinctive phenotypes to further homogenize subtypes of BD for genetic analyses. 2, 3 In this regard, recent observations of higher basal intracellular calcium levels ( B-lymphoblast cell lines (BLCLs) derived from BD-I patients compared with healthy subjects 4 may reflect a trait-dependent alteration in intracellular calcium homeostasis and a putative cellular 'endophenotype' of BD. Similarly, the activity and expression of myoinositol monophosphatase (IMPase), a key lithiumsensitive enzyme in phosphoinositide (PI) signaling, 5 was found to be lower in BLCLs 6 and lymphocytes, 7 respectively, from BD patients and may also reflect another potential endophenotype of BD. The importance of IMPase in regulating the recycling of myo-inositol and subsequently phosphatidylinositol bisphosphate formation, PI signaling and intracellular calcium mobilization, is well established. 8, 9 This raises the possibility that the disturbances in intracellular calcium homeostasis identified in BLCLs from BD-I patients may be associated with the reduced IMPase expression. To date, two isoforms of IMPase have been cloned and characterized at the genomic level. The IMPA1 gene encoding IMPase 1 has been mapped to the chromosomal region 8q21 10 whereas IMPA2, which encodes IMPase 2, has been localized to chromosomal region 18p11.2, 11 one of several potential BD susceptible chromosomal loci. 12 Understanding of the molecular and biochemical characteristics of IMPase 1 in mammalian cells has advanced considerably during the past decade, 13 in contrast to IMPase2, about which less is known at present. We report here a sex-dependent reduction in IMPase2 mRNA levels in BLCLs from male BD-I patients showing high [Ca 2+ ] B compared with male BD-I patients with normal [Ca 2+ ] B and healthy male subjects, supporting the notion that these putative cellular phenotypes may be associated, at least in a subgroup of BD-I patients.
Materials and methods

B-lymphoblast cell lines (BLCLs) and postmortem brain
BLCLs were from a subset of the BD-I patients and matched healthy subjects on whom we have previously reported [Ca 2+ ] B . 4 Physically healthy BD-I patients were recruited from the outpatient and inpatient mood disorders clinics of the Clarke Institute of Psychiatry, and nonpsychiatric comparison subjects by posted advertisement. Subjects were assessed as previously described using the SCID-I/P or I/NP versions for patients and healthy subjects, respectively. Following expansion in culture for 13-16 passages, [Ca 2+ ] B was determined in aliquots of BLCLs (1 × 10 6 cells) from 24 BD-I and 12 healthy subjects by ratiometric spectrofluorometry using fura-2, as reported previously. 4 − reverse transcriptase (Gibco BRL). The reaction mixture was incubated for 1 h at 42°C and the reaction stopped by heating for 15 min at 70°C. Eighty microliters of water were added to dilute the mixture and the aliquoted cDNAs were stored at −20°C until use.
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Comparative RT-PCR assay Due to the limited quantity of the RNA from tissues and in order to minimize potential inter-and intraassay variability, we employed a relative quantitative multiplex RT-PCR procedure using a commercially available kit (Quantum RNA TM 18S internal standards, Ambion, Austin, TX). This is a semi-quantitative method that uses 18S rRNA as an internal control against which the amplified cDNA of interest is normalized. 15 The identity of PCR products was confirmed by DNA sequencing of both strands (data not shown).
Amplification of human IMPA1 cDNA was performed as described in a previous report. 6 For quantification of human IMPA2, primer pairs for PCR amplification were designed based on the cDNA sequence reported previously; 11 IMPA2-5, 5Ј-CGT GAT AGA CAC TTC GGG TG-3Ј and IMPA2-3, 5Ј-GCC ACT CAC TGT AGC GTG AC-3Ј. Primers were directed to sequences in the 3Ј end of the coding region and a part of untranslated region, and amplified a fragment of 281 bp. Co-amplification of 18S rRNA in the same tube was performed using a kit (Classic 18S Internal Standards, Ambion) that generated a 488-bp product. In preliminary experiments, amplification of PCR products from the IMPA1 and IMPA2 templates was found to be linear between 24 and 34 cycles of PCR. Furthermore, the ratios of 18S rRNA/IMPA1 and IMPA2 mRNA did not vary significantly with the amount of sample loaded between 0.5 and 2.0 l of diluted first strand cDNA (data not shown).
The conditions for PCR were: initiation at 95°C for 15 min, 28 cycles consisting of 94°C for 45 s, 59°C for 45 s, and 72°C for 1 min, and final extension at 72°C for 5 min in a MJ thermocycler. The 20-l PCR mixture contained 1 l of 5-fold diluted first strand cDNA, 2 l of 10× PCR buffer (Qiagen), 0.4 l of 10 mM dNTPs, 0.2 l HotStarTaq DNA polymerase (Qiagen, 5 U l −1 ), 1.6 l of 10 M IMPA primer mix, 3.2 l of 5 M 18S primer and competimer mix (ratio 1:9, Ambion), and 0.2 l of [␣-
33 P]-dATP (DuPont NEN, 10 mCi ml −1 ). Five microliters of the final reactions were mixed with 5 l of 2× formamide gel loading buffer and denatured at 95°C for 2 min. Nine microliters of the mixtures were loaded onto a denaturing 6% polyacrylamide gel and resolved in the presence of 1× Tris-Borate EDTA buffer (pH 8.3) for 2 h at 180 V. Gels were then transferred to 3-mm filter paper and dried under vacuum at 80°C for 2 h. The relative intensities of IMPAs and 18S rRNA bands were measured using a Storm phosphoimaging system and ImageQuant software (Molecular Dynamics). The level of expression of the IMPA transcript was calculated as the ratio of the IMPA band to the 18S rRNA band.
Statistical analysis
Differences in dependent measures among phenotypic or diagnostic groups were analysed by two-way analysis of variance (ANOVA) with phenotype, or diagnosis and sex as factors, followed by post hoc comparisons of group means using the Tukey test. Interactions were further analysed by examining simple effects of pheno-type or diagnosis within sex. 16 In some instances, Student's t-tests for independent samples were performed. Correlations were determined using the Pearson product-moment test. Statistical differences with twotailed probability values of P Ͻ 0.05 were taken as significant. The SPSS (version 10) statistical package was used to perform statistical analyses. Table 1 summarizes the demographics, state of illness and mood stabilizer treatments for the subjects studied. There were no significant differences in age among the phenotypic (healthy, BD-I with normal BLCL [Ca ] B were found to be receiving lithium monotherapy at the time of study. BLCL IMPA1 and 2 mRNA levels IMPA1 transcript levels in BLCLs did not differ among the two BD-I patient and healthy subject groups (F = 1.13, df = 2,30, P = 0.34, two-way ANOVA). There was also no difference when healthy subjects were compared with the combined BD-I patient group (t = 1.58, df = 34, P = 0.12, Student's t-test). While there were no main effects of phenotype (F = 0.29, df = 2,30, P = 0.75) or sex (F = 1.88, df = 1,30, P = 0.18) on IMPA2 mRNA levels, a significant interaction was found between phenotype and sex (F = 7.57, df = 2,30, P = 0.002, Figure 1b) . Post hoc analysis of simple effects revealed significantly lower IMPA2 mRNA levels in the male BD-I high [Ca 2+ ] B group compared with healthy male subjects (P = 0.013), male BD-I patients with normal [Ca 2+ ] B (P = 0.003) and female BD-I patients with high BLCL [Ca 2+ ] B (P = 0.0004). However, there was no difference in IMPA2 mRNA levels between healthy and BD-I subjects as a whole (t = 0.1, df = 34, P = 0.99, Student's t-test). The above finding of reduced IMPA2 mRNA levels was not attributable to a difference in the absolute band densities of 18S rRNA signal as the latter did not differ significantly among the samples of comparison groups in either the IMPA1 (ie F = 1.6, df = 2,30, P = 0.23) or IMPA2 assays (F = 0.7, df = 2,30, P = 0.52). Given the statistically significant interaction between sex and [Ca 2+ ] B phenotype in BD-I patients, we examined whether [Ca 2+ ] B correlated with IMPA2 expression in BLCLs from male and female BD-I subjects. Interestingly, there was a significant inverse correlation (r = −0.54, P = 0.046, n = 14) between these variables in BLCLs from male BD-I subjects, whereas there was a trend toward a significant positive correlation in BLCLs from female BD-I subjects (r = 0.60, P = 0.067, n = 10).
Results
Subject characteristics
Since post hoc examination revealed more male (8/14) than female (3/10) BD-I patients were receiving lithium treatment at the time of blood collection, either as a monotherapy or in combination with an anticonvulsant mood stabilizer or neuroleptic, we also examined whether a therapeutically relevant concentration of lithium affects IMPA2 gene expression in BLCLs from BD-I patients. However, IMPA2 mRNA levels did not differ significantly from baseline in individual cell lines from eight BD-I patients (two male and two female each from high Ca 2+ and normal Ca 2+ BD-I phenotypes) incubated with 0.75 mM of lithium or vehicle for 7 days (data not shown).
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Temporal cortex IMPA2 and IMPA1 mRNA levels A variety of reports implicate temporal cortex as one of several particularly suspect brain regions showing abnormalities in measures of signal transduction processes, in morphometric investigations, and in vivo neuroimaging in BD. 17, 18 Thus, to assess whether IMPA2 mRNA levels are also altered in brain from BD-I patients, as observed in BLCLs, we measured IMPA2 transcript levels in postmortem temporal cortex from BD-I patients, and age-, sex-, and PMI-matched nonpsychiatric comparison subjects (n = 9 per group). Twoway ANOVA revealed a significant sex by diagnosis interaction (F = 6.43, df = 1,14, P = 0.024, Figure 2 ) between comparison groups, but no main effect of diagnosis (F = 1.45, df = 1,14, P = 0.252). Post hoc analysis of simple effects revealed significantly higher IMPA2 mRNA levels in male BD-I patients compared with male controls (F = 6.26, df = 1,14, P = 0.025, Figure 2 ). IMPA2 mRNA levels did not correlate significantly with lithium concentrations (r = −0.27, P = 0.52, n = 8), however, in those BD brains showing detectable lithium levels. In contrast, no differences were detected in temporal cortical IMPA1 mRNA levels between BD and comparison subjects (data not shown).
Discussion
The main finding in this report is the significantly reduced steady-state IMPA2 mRNA levels in BLCLs Figure 2 Expression level of IMPA2 mRNA in postmortem temporal cortex from BD patients and nonneurological, nonpsychiatric control subjects matched on age, sex and postmortem interval. Data are expressed as the means ± SD for the number of subjects indicated on the bars. Two-way ANOVA revealed a significant sex by diagnosis interaction (F = 6.434, df = 1,14, P = 0.024). Post-hoc analysis of simple effects revealed significantly higher IMPA2 mRNA level in male BD-I as compared with male controls (F = 6.26, df = 1,14, *P = 0.025). from male BD-I patients who exhibited elevated BLCL [Ca 2+ ] B . In contrast, no differences were found in IMPA1 mRNA levels among comparison groups. The significantly reduced IMPA2 gene expression found in male BD-I patients, most of whom were receiving lithium, is not likely due to the pharmacological effect of this drug in vivo on the B lymphocytes that were subsequently transformed. The BLCLs were cultured in a drug-free media for 13-16 passages (ie medium changes) after isolation and transformation. In addition, exposure of BLCLs from BD-I patients to lithium for 7 days did not alter IMPA2 transcript levels, unlike the change in IMPA1 expression reported by others. 6 This suggests that those cell lines with lower IMPA2 transcripts may display genetically different characteristics compared with other BD-I cell lines. It remains to be demonstrated whether this is a primary disease characteristic of the subgroup of BD-I patients showing intracellular calcium homeostasis abnormalities, or an effect of an extraneous factor(s) that influences the selection and transformation of B lymphocyte populations of different ages, with different levels of IMPA2 expression, from BD-I patients with calcium homeostasis abnormalities compared with controls.
Recently, Shamir et al 6 reported that IMPase activity is reduced in BLCLs from BD patients, particularly in lithium responders compared with controls. However, the extent to which the activity determined reflects IMPase 1 vs IMPase 2 was not addressed and indeed as such must be regarded as representing the total lithium-sensitive IMPase activity until demonstrated otherwise. Thus, it is still plausible that altered IMPase 2 activity also contributes to the reduction in total IMPase activity in BLCLs from BD patients. 6 The results of this study also suggest a potential sex difference in IMPA2 gene expression in BLCLs and postmortem brain from BD subjects. In this regard, two previous studies observed sex differences in other biochemical/cellular indices in BD patients. Samuelson et al 19 reported higher cerebrospinal fluid (CSF) protein levels in male as compared with female bipolar depressed patients. Furthermore, Emamghoreishi et al 20 found a sex difference in basal and NaF-stimulated cAMP production in BLCLs membranes. The divergent correlations between IMPA2 transcript level and [Ca 2+ ] B in BLCLs from male (inverse) and female (positive) BD-I patients, and our data from postmortem temporal cortex, suggest potential sex differences also occur in IMPA2 gene expression in BD-I.
We found no statistical differences in mean IMPA1 or 2 mRNA expression levels among comparison groups stratified by IMPA1 and 2 genotype using recently reported polymorphisms (A/G transition in 3Ј untranslated region of IMPA1 10 ) and T-C silent mutation in exon 2 of IMPA2 21 of each gene for the analysis (unpublished). Thus, it is not possible to ascribe the present findings to genetic variation and specific IMPA1 and 2 gene variants. The total sample size (n = 36) in which both mRNA expression levels and genotyping data have been obtained in this study is small, however, and in the case of IMPA2, the polymorphism on which subjects were typed is relatively rare.
In contrast to the findings in BLCLs, IMPA2 mRNA levels in temporal cortex from male BD patients was significantly higher than those from male control subjects. This may be explained, in part, by the different ontogenesis of these tissues. That is, IMPA2 gene expression in these tissues may be regulated differently within the genetic 'environment' of BD. In support of this notion, decreased IMPase activity was found in BLCLs from BD patients compared with controls, 6 while no difference was found in the activity of this enzyme in autopsied frontal and occipital cortex, and cerebellum 22 between the two comparison groups. Other plausible explanations for the discordant observations between brain and BLCL, include the effects of medications, state-related illness factors, or causes of death that modify IMPA2 expression in brain but not BLCLs, which were cultured in the absence of these factors. We did not find any differences in mean PMI between BD and control brain, however. There was also no correlation between PMI, concentration of lithium in BD brain, or age of BD patients with IMPA2 transcript level. Furthermore, there was no cause of death common to all male BD patients that could account for the divergent findings.
The present observations must be considered against the backdrop of several potentially important limitations to the current study design that could affect the interpretation of the results. These include the small sample size, heterogeneity of the study populations that may be related to other phenotypic characteristics such as age of onset, bipolar phenotype (eg history of psychotic vs non psychotic episodes; rapid cycling), genetic etiology (sporadic vs familial), other psychiatric comorbidity, and ethnicity. In addition, while BLCL [ Ca   2+ ] B appears to be constant across passages (up to 48) and replicate transformations of B lymphocytes from the same leukocyte preparations give similar [Ca 2+ ] B (unpublished), the stability across time and passage of the mRNA species measured here remains to be demonstrated. A final caveat is that changes in mRNA levels do not necessarily predict functional consequences; that requires confirmation by directly characterizing the protein levels and function.
These limitations, notwithstanding, our data provide the first evidence suggesting that there may be a relationship between altered IMPA2 gene expression and abnormal calcium homeostasis as reflected by elevated [Ca 2+ ] B in BLCLs from a subgroup of BD patients. Although little is known regarding the transcriptional regulation of IMPA2 by calcium transduction mechanisms, it is possible that the reduced IMPA2 mRNA levels in male BD-I patients found here are a result of calcium-mediated suppression of IMPA2 expression or destabilization of its mRNA. It is also possible that changes in IMPA2 gene expression may lead to an alteration of calcium homeostasis as suggested in a recent study 23 which showed that calcium signaling can be altered by inhibition of IMPase activity. In this regard, it will be important to test whether changing [Ca 2+ ] B by such techniques as 'clamping' affects IMPA gene expression or whether knock-out or overexpression of the IMPA genes alters the calcium signaling. The extent to which IMPA2 contributes to inositol recycling as compared to IMPA1, as well as whether lithium preferentially inhibits one or the other of these isozymes, is unknown. Consequently, it is not possible at this time to relate these differences in IMPA2 mRNA levels to the inhibitory effects of lithium on IMPase activity, nor the inositol depletion hypothesis of lithium action.
In summary, findings of sex-dependent differences in IMPA2 mRNA levels in patients with BD-I disorder and the association of these changes with an index of abnormal calcium homeostasis suggest these alterations characterize a subtype of this illness. Since the IMPA2 gene is located in a chromosomal region suggested to be a potential BD susceptibility locus 11 and IMPase activity plays a key role in PI/Ca 2+ signaling, it is plausible that the gene product of IMPA2 plays an important role, along with other factors regulating calcium homeostasis, in the pathophysiology of BD. Further support for this notion awaits the determination of protein levels in postmortem brain and BLCLs from BD patients using antibody specific to IMPase2, along with the measurement of its functional activity. Equally important is the relationship to lithium response as raised in the observations of Shamir et al. 6 
